Zyprexa 3rd-Party Payers' Class Bid Draws Flak

Law360, New York (May 22, 2008, 12:00 AM EDT) -- The multidistrict litigation over Eli Lilly & Co.'s anti-psychotic drug Zyprexa is “fundamentally different” from the ongoing putative class action over the drug industry's average wholesale prices, and a decision in that case should not influence Lilly's case, Lilly's lawyers told the MDL judge Thursday.

In a letter sent Thursday to Judge Jack B. Weinstein of the U.S. District Court for the Eastern District of New York, Lilly's lawyers claimed the First Circuit Court of Appeals' ruling on class certification in the AWP case is “irrelevant”...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.